Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. - Wikidata - wikimedia - TriplyDB

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.

http://www.wikidata.org/entity/Q37541523

about

A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies.Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients.

P2860

Q50108934-D13A1BC2-7E9A-4A25-A9E7-C03074A1DF99 Q54989077-442EBD20-EBD7-436F-9AA9-57564D3BF3BD

P2860

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.

http://www.wikidata.org/entity/Q37541523

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.

@en

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.

@nl

type

label

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.

@en

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.

@nl

prefLabel

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.

@en

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.

@nl

P1433

Q37541523-97FC45D6-ED6E-47D7-AE97-9FF5F894C87F

P1476

Q37541523-7A3D3120-4EFC-4346-91EF-4024EAB63E94

P2093

Q37541523-1AE7534C-3DEC-4AB8-B4D1-3CC6A85A578C

Q37541523-BE7CCFAA-CA79-45F7-B6D1-4F73C5468082

Q37541523-D2805F82-145E-4BAB-A91C-55B858816228

P275

Q37541523-E7817351-A3F3-4EC5-AFC1-63121390A042

P2860

Q37541523-039C7E08-B5D2-4CA7-8C63-83E7EA448875

Q37541523-03DA33ED-1B53-48F1-BC38-9A324F45C741

Q37541523-0442BD43-26E2-4B78-A428-F2867BBCBCE7

Q37541523-1407D205-7290-491E-A749-676C64DE3B5B

Q37541523-15535D41-1F9F-4204-8328-480F2C975FA6

Q37541523-2696F427-DC76-4E4E-84A2-776A4D0EC473

Q37541523-2FC7211A-A71E-4002-81F6-8AF243085B69

Q37541523-2FFD0A34-AC65-4609-8D7D-CD7F75A2DB9F

Q37541523-32783316-A4D5-4AE8-B8D7-B98042C1CA62

Q37541523-363A2BBB-E0D9-44A0-AB8A-481A8AFEA5E2

P2888

Q37541523-8285DC27-6FB4-42A1-BC6E-2E18A4F5AD65

P304

Q37541523-0C267F57-9AC5-4835-A7A1-17DE9043C603

P31

Q37541523-5FC6BB98-2389-4FBE-ADB5-24E1A236B28B

Q37541523-D9FE7A89-737C-4A38-A028-DA394655BFAD

P356

Q37541523-7A495193-453A-4E29-91A1-CFD09256EAE3

P433

Q37541523-43F52315-C4A5-4840-925A-95EED9EE0241

P478

Q37541523-78B58C1A-FA3B-464F-B5A1-60573C3264EA

P50

Q37541523-A3601373-8D4C-4A58-B691-D65AADC54994

P5008

Q37541523-57FEFDD0-E4C8-40D9-A8F7-9CE9FEAE7C3E

P577

Q37541523-111CD4C8-3F92-4C6D-A36F-78618D06D13F

Q37541523-709BE8C4-3C45-48FB-A549-E5F6C8FEBD3B

P698

Q37541523-7040ECC9-8A34-47E5-AABA-EAC85A0BC284

P921

Q37541523-00A30CE2-DB76-460D-A2B2-D10564FC90F2

Q37541523-1AA727C0-9B8A-443C-8D7E-E0325EB1B2EA

Q37541523-3FE9DA35-CE2F-41A4-82EC-90F391265C97

Q37541523-49C83BA8-830F-45AA-BAD2-4156770113E7

Q37541523-618E2E12-54E4-4C8C-B657-628C023E7FA0

Q37541523-65B296EE-B346-46FE-9D66-79D53FE7D99A

P932

Q37541523-5684F571-852C-41D3-A668-45A0F31EC626

P356

S00520-016-3419-4

P1433

Supportive Care in Cancer

P1476

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.

@en

P2093

Bernd Tischer

http://www.w3.org/2001/XMLSchema#string

Matthias Kraemer

http://www.w3.org/2001/XMLSchema#string

Renate Huber

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer

Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer

Erlotinib in previously treated non-small-cell lung cancer

Psychological sequelae and alopecia among women with cancer.

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

P2888

s00520-016-3419-4

P304

651-660

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-016-3419-4

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Mario E Lacouture

P5008

P577

2016-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27718067

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

membrane proteins

biomedical investigative technique

P932

5196015

http://www.w3.org/2001/XMLSchema#string